Page 2 of 4, showing 50 records out of 165 total, starting on record 51, ending on 100
| Publication |
Category |
Year |
|
426. Couillard, S., Labrie, C., Bélanger, A., Candas, B., Pouliot, F., Labrie, F. (1998) Effect of dehydroepiandrosterone and the antiestrogen EM-800 on growth of human ZR-75-1 breast cancer xenografts. J. Natl. Cancer Inst., 90: 772-778. |
DHEA |
1998 |
|
637. Cusan, L., Dupont, A., Gomez, J.L., Tremblay, R.R., Labrie, F. (1994) Comparison of Flutamide and spironolactone in the treatment of hirsutism: a randomized controlled trial. Fertil. Steril., 61: 281-287. |
DHEA |
1994 |
|
632. Dalla Valle, L., Couet, J., Labrie, Y., Simard, J., Belvedere, P., Simontacchi, C., Labrie, F., Colombo, L. (1995) Occurrence of cytochrome 450c17 mRNA and dehydroepiandrosterone biosynthesis in the rat gastrointestinal tract. Mol. Cell. Endocrinol., 111: 83-92. |
DHEA |
1995 |
|
363. Diamond, P., Cusan, L., Gomez, J.L., Bélanger, A., Labrie, F. (1996) Metabolic effects of 12-month percutaneous DHEA replacement therapy in postmenopausal women. J. Endocrinol., 150 Suppl.: S43-S50. |
DHEA |
1996 |
|
387. Dimitrakakis, C., Zhou, J., Wang, J., Belanger, A., Labrie, F., Cheng, C., Powell, D., Bondy, C. (2003) A physiologic role for testosterone in limiting estrogenic stimulation of the breast. Menopause, 10: 292-298. |
DHEA |
2003 |
|
571. Eriksson, A.L., Lorentzon, M., Mellstrom, D., Vandenput, L., Swanson, C., andersson, N., Hammond, G.L., Jakobsson, J., Rane, A., Orwoll, E.S., Ljunggren, O., Johnell, O., Labrie, F., Windahl, S.H., Ohlsson, C. (2006) SHBG gene promoter polymorphisms in men are associated with serum sex hormone-binding globulin, androgen and androgen metabolite levels, and hip bone mineral density. J Clin Endocrinol Metab, 91: 5029-37. |
DHEA |
2006 |
|
4696. Eriksson, A.L., Lorentzon, M., Vandenput, L., Labrie, F., Lindersson, M., Syvänen, A.C., Orwoll, E.S., Cummings, S.R., Zmuda, J.M., Ljunggren, O., Karlsson, M.K., Mellström, D., Ohlsson, C. (2009) Genetic Variations in Sex Steroid-Related Genes as Predictors of Serum Estrogen Levels in Men. J. Clin Endocrinol, Metab, 94: 1033-1041. |
DHEA |
2009 |
|
4697. Faucher, F., Cantin, L., Luu-The, V., Labrie, F., Breton, F. (2008) Crystal structures of human Delta4-3-ketosteroid 5beta-reductase (AKR1D1) reveal the presence of an alternative binding site responsible for substrate inhibition. Biochemistry, 47: 13537-13546. |
DHEA |
2008 |
|
4685. Faucher, F., Cantin, L., Luu-The, V., Labrie, F., Breton, F. (2008) The crystal structure of human delta4-3-ketosteroid 5beta-reductase defines the functional role of the residues of the catalytic tetrad in the steroid double bond reduction mechanism. Biochemistry, 47: 8261-8270. |
DHEA |
2008 |
|
572. Faucher, F., Pereira de Jésus-Trans, K., Cantin, L., Luu-The, V., Labrie, F., Breton, R. (2006) Crystal structures of mouse 17beta-hydroxysteroid dehydrogenase (Apoenzyme and enzyme-NADP(H) binary complex): Identification of molecular determinants responsible for the unique 17beta-reductive activity of this enzyme. J.Mol. Biol., 364: 747-763. |
DHEA |
2006 |
|
4703. Forsblad d'Elia, H., Carlsten, H., Labrie, F., Konttinen, Y., Ohlsson, C. (2009) Low serum levels of sex-steroids are associated with disease characteristics in primary Sjögren's syndrome; supplementation with dehydroepiandrosterone restores the concentrations, J Clin Endocrinol Metab, 94: 2044-51. |
DHEA |
2009 |
|
96. Labrie, C., Flamand, M., Bélanger, A., Labrie, F. (1996) High bioavailability of DHEA administered percutaneously in the rat. J. Endocrinol., 150: S107-S118. |
DHEA |
1996 |
|
167. Labrie, C., Simard, J., Poulin, M., Bélanger, A., Pelletier, G., Labrie, F. (1990) Influence of the duration of androgen deprivation on the sensitivity of the rat ventral prostate to dehydroepiandrosterone and androstenedione. In: Bradlow, H., Castagnetta, L., d'Aquino, S. et Labrie, F. eds. Steroid Formation, Degradation and Action in Peripheral Tissues, Normal and Neoplastic Tissues. Ann. New York Acad. Sci. pp 392-394. |
DHEA |
1990 |
|
168. Labrie, C., Simard, J., Zhao, H.F., Bélanger, A., Pelletier, G., Labrie, F. (1990) Stimulation of androgen-dependent gene expression by the adrenal precursors dehydroepiandrosterone and androstenedione in the rat ventral prostate. In: Bradlow, H., Castagnetta, L., d'Aquino, S. et Labrie, F. eds. Steroid Formation, Degradation and Action in Peripheral Tissues, Normal and Neoplastic Tissues. Ann. New York Acad. Sci. pp 395-398. |
DHEA |
1990 |
|
160. Labrie, F. (1991) Intracrinology. Mol. Cell. Endocrinol., 78: C113-C118. |
DHEA |
1991 |
|
135. Labrie, F. (1993) Intracrinology: its impact on prostate cancer. Curr. Opin. Urol., 3: 381-387. |
DHEA |
1993 |
|
124. Labrie, F. (1994) Intracrinology and Cancer Therapy. Science Watch, 5: 3-4. |
DHEA |
1994 |
|
34. Labrie, F. (2002) Endocrine-sensitive cancers of the prostate and breast, in: Baster, J., Melmed, S. et New, M., eds: Genetics in Endocrinology, Lippincott-William and Wilkins, pp 607-661. |
DHEA |
2002 |
|
30. Labrie, F. (2003) Hormonal therapy in the management of prostate cancer at all stages of the disease, in: Syrigos, K.N., ed. Prostate Cancer: Biology, Diagnosis and Management, London, UK, Oxford University Press, pp 301-314. |
DHEA |
2003 |
|
21. Labrie, F. (2004) Current status of endocrine therapy in localized prostate cancer: cure has become a strong possibility. Brazilian J Urol, 30: 3-12. |
DHEA |
2004 |
|
22. Labrie, F. (2004) Major role of androgen blockade in the success of prostate cancer treatment: cure has become a very good possibility. Prostate Cancer Communication Newsletter, 20: 3-11. |
DHEA |
2004 |
|
23. Labrie, F. (2004) Medical castration with LHRH agonists: 25 years later with major benefits achieved on survival in prostate cancer. J Androl, 25: 305-313. |
DHEA |
2004 |
|
573. Labrie, F. (2006) Dehydroepiandrosterone, androgens and the mammary gland. Gynecological Endocrinol: the official journal of the International Soc. of Gynecological Endocrinol, 22: 118-30. |
DHEA |
2006 |
|
380. Labrie, F. (2006) Future perspectives of selective estrogen receptor modulators used alone and in combination with DHEA. Endocr Relat Cancer, 13: 335-355. |
DHEA |
2006 |
|
16. Labrie, F. (2006) Keyrole of endocrinology in the victory against prostate cancer. Bull. Cancer, 93: 949-58. |
DHEA |
2006 |
|
355. Labrie, F. (2007) Drug insight: breast cancer prevention and tissue-targeted hormone replacement therapy. Nat Clin Pract Endocrinol Metab, 3: 584-93. |
DHEA |
2007 |
|
374. Labrie, F. (2008) Combination of Breast Cancer Prevention with Tissue-Targeted Hormone Replacement Therapy, In: Breast Cancer - Prognosis, Treatment, and Prevention, Second Edition, Pasqualini, J.R., ed., pp. 201-252. |
DHEA |
2008 |
|
4710. Labrie, F. (2010) DHEA after Menopause – Sole source of sex steroids and potential sex steroid deficiency treatment. Menopause Management. 19: 14-24 |
DHEA |
2010 |
|
4700. Labrie, F., Archer, D., Bouchard, C., Fortier, M., Cusan, L., Gomez, J.L., Girard, G., Baron, M., Ayotte, N., Moreau, M., Dubé, R., Côté, I., Labrie, C., Lavoie, L., Berger, L., Gilbert, L, Balser, J. (2009) Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women, Menopause, 16: 923-931. |
DHEA |
2009 |
|
4701. Labrie, F., Archer, D., Bouchard, C., Fortier, M., Cusan, L., Gomez, J.L., Girard, G., Baron, M., Ayotte, N., Moreau, M., Dubé, R., Côté, I., Labrie, C., Lavoie, L., Berger, L., Gilbert, L, Martel, C., Balser, J. (2009) Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy, Menopause, 16: 907-922. |
DHEA |
2009 |
|
4702. Labrie, F., Archer, D., Bouchard, C., Fortier, M., Cusan, L., Gomez, J.L., Girard, G., Baron, M., Ayotte, N., Moreau, M., Dubé, R., Côté, I., Labrie, C., Lavoie, L., Berger, L., Gilbert, L, Martel, C., Balser, J. (2009) Serum steroid levels during 12-week intravaginal dehydroepiandrosterone administration, Menopause, 16: 897-906. |
DHEA |
2009 |
|
576. Labrie, F., Bélanger, A., Bélanger, P., Bérubé, R., Martel, C., Cusan, L., Gomez, J., Candas, B., Castiel, I., Chaussade, V., Deloche, C., Leclaire, J. (2006) Androgen glucuronides, instead of testosterone, as the new markers of androgenic activity in women. J Steroid Biochem Mol Biol, 99: 182-188. |
DHEA |
2006 |
|
559. Labrie, F., Bélanger, A., Bélanger, P., Bérubé, R., Martel, C., Cusan, L., Gomez, J., Candas, B., Chaussade, V., Castiel, I., Deloche, C., Leclaire, J. (2007) Metabolism of DHEA in postmenopausal women following percutaneous administration., 103: 178-88. |
DHEA |
2007 |
|
577. Labrie, F., Bélanger, A., Bélanger, P., Bérubé, R., Martel, C., Cusan, L., Gomez, J.L., Candas, B., Chaussade, V., Castiel, I., Deloche, C., Leclaire, J. (2006) Metabolism of DHEA in postmenopausal women following percutaneous administration. J Steroid Biochem Mol Biol, 103: 178-88. |
DHEA |
2006 |
|
622. Labrie, F., Bélanger, A., Cusan, L., Candas, B. (1997) Physiological changes in DHEA are not reflected by the serum levels of active androgens and estrogens but of their metabolites: intracrinology. J. Clin. Endocrinol. Metab., 82: 2403-2409. |
DHEA |
1997 |
|
623. Labrie, F., Bélanger, A., Cusan, L., Gomez, J.L., Candas, B. (1997) Marked decline in serum concentrations of adrenal C19 sex steroid precursors and conjugated androgen metabolites during aging. J. Clin. Endocrinol. Metab., 82: 2396-2402. |
DHEA |
1997 |
|
139. Labrie, F., Bélanger, A., Dupont, A., Luu-The, V., Simard, J., Labrie, C. (1993) Science behind total androgen blockade: from gene to combination therapy. Clin. Invest. Med., 16: 475-492. |
DHEA |
1993 |
|
560. Labrie, F., Bélanger, A., Labrie, C., Candas, B., Cusan, L., Gomez, J.L. (2007) Bioavailability and metabolism of oral and percutaneous dehydroepiandrosterone in postmenopausal women. J Steroid Biochem Mol Biol, 107: 57-69. |
DHEA |
2007 |
|
19. Labrie, F., Bélanger, A., Luu-The, V., Labrie, C., Simard, J., Cusan, L., Gomez, J., Candas, B. (2005) Gonadotropin-releasing hormone agonists in the treatment of prostate cancer. Endocrine Reviews, 26: 361-379. |
DHEA |
2005 |
|
399. Labrie, F., Bélanger, A., Luu-The, V., Simard, J., Labrie, C. (2001) DHEA replacement therapy as source of androgens and estrogens at menopause, in: Genazani, A.R., Petraglia, F. et Artini, P.G., eds: Advances in Gynecological Endocrinology, London, UK, Parthenon Publishing, pp 249-258. |
DHEA |
2001 |
|
395. Labrie, F., Bélanger, A., Luu-The, V., Simard, J., Labrie, C. (2002) DHEA replacement therapy as a source of androgens and estrogens at menopause, in: Genazzani, A.R., Petraglia, F. et Artini, P.G., eds: Advances in Gynecological Endocrinology, Florence, Italy, Parthenon Publishing, pp 249-258. |
DHEA |
2002 |
|
634. Labrie, F., Bélanger, A., Simard, J., Luu-The, V., Labrie, C. (1995) DHEA and peripheral androgen and estrogen formation: intracrinology. Ann. N.Y. Acad. Sci., 774: 16-28. |
DHEA |
1995 |
|
111. Labrie, F., Bélanger, A., Simard, J., Luu-The, V., Labrie, C. (1995) Intracrinologie: autonomie et liberté des tissus périphériques. Ann. Endocrinol. (Paris), 56: 23-29. |
DHEA |
1995 |
|
98. Labrie, F., Bélanger, A., Simard, J., Luu-The, V., Labrie, C., Cusan, L., Gomez, J., Diamond, P., Candas, B. (1996) Sources d'androgènes chez l'homme et traitement hormonal du cancer de la prostate (Chapter 16), in: Belaisch, J., Drodowsky, M.A. et Vermeulen, A., eds: Progrès en Andrologie: Endocrinologie Masculine, Doin, pp 215-229. |
DHEA |
1996 |
|
61. Labrie, F., Bélanger, A., Simard, J., Luu-The, V., Labrie, C., Lin, S.-X., Candas, B., Cusan, L. (1999) Impact de l'intracrinologie dans la thérapeutique et la prévention des cancers du sein et de la prostate et de la ménopause, in: Guérité, N. et Leclère, J., eds: Mises au point cliniques d'endocrinologie, nutrition et métabolisme 1999, Paris, France, Les Éditions de Médecine Pratique, pp 169-204. |
DHEA |
1999 |
|
25. Labrie, F., Candas, B., Cusan, L., Gomez, J.L., Bélanger, A., Brousseau, G., Lévesque, J. (2004) Screening decreases prostate cancer mortality: 11-year follow-up on the 1988 Quebec prospective randomized controlled trial. The Prostate, 59: 311-318. |
DHEA |
2004 |
|
4690. Labrie, F., Cusan, L., Gomez, J.L., Côté, I., Bérubé, R., Bélanger, P., Martel, C., Labrie, C. (2008) Corrigendum to: Effect of Intravaginal DHEA on Serum DHEA and Eleven of its Metabolites in Postmenopausal Women. J Steroid Biochem Mol Biol, 112: 169 |
DHEA |
2008 |
|
1087. Labrie, F., Cusan, L., Gomez, J.L., Côté, I., Bérubé, R., Bélanger, P., Martel, C., Labrie, C. (2008) Effect of Intravaginal DHEA on Serum DHEA and Eleven of its Metabolites in Postmenopausal Women. J Steroid Biochem Mol Biol, 111: 178-194 |
DHEA |
2008 |
|
353. Labrie, F., Cusan, L., Gomez, J.L., Côté, I., Bérubé, R., Bélanger, P., Martel, C., Labrie, C. (2009) Effect of One-Week Treatment with Vaginal Estrogen Preparations on Serum Estrogen Levels in Postmenopausal Women. Menopause, 16: 30-36. |
DHEA |
2009 |
|
31. Labrie, F., Cusan, L., Gomez, J.L., Candas, B., Bélanger, A., Luu-The, V., Simard, J. (2003) De la biologie à la clinique: le décès dû au cancer de la prostate peut-il maintenant être une exception? Médecine/Sciences, 19: 910-19. |
DHEA |
2003 |